{
    "clinical_study": {
        "@rank": "88961", 
        "arm_group": {
            "arm_group_label": "NKT cells", 
            "arm_group_type": "Experimental", 
            "description": "NKT cells treatment plus regular treatment"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and effectiveness of  natural killer T\n      (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic,\n      treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung\n      cancer, pancreatic cancer, colon cancer or prostate cancer."
        }, 
        "brief_title": "Autologous Natural Killer T Cells Infusion for the Treatment of Cancer", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Glioma", 
            "Hepatocellular Cancer", 
            "Squamous Cell Lung Cancer", 
            "Pancreatic Cancer", 
            "Colon Cancer", 
            "Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Glioma", 
                "Liver Neoplasms", 
                "Lung Neoplasms", 
                "Pancreatic Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized controlled trial on the efficacy and safety of autologous natural killer T\n      (NKT) cells infusion treatment in advanced cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\u2022Male or female not less than 18 years of age or over 80 years of age.\n\n          -  Life expectancy of \u2265 24 weeks as measured by the Eastern Cooperative Oncology Group\n             (ECOG) performance status.\n\n          -  Subjects must present with one of the following disease pathologies: Breast Cancer,\n             Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon\n             Cancer or Prostate Cancer\n\n          -  The pathology must be an assessable disease (measurable by CT scan or MRI) that is\n             refractory to standard treatments (e.g., chemotherapy, radiation, etc.)\n\n          -  Negative for hepatitis B, hepatitis C, HIV, and CMV.\n\n          -  Subjects must present with leukocyte counts above 3,000/\u03bcL and platelet counts above\n             100,000/ \u03bcL.\n\n          -  Subjects must present with minimum hemoglobin levels of 10.\n\n          -  If female, subject is surgically sterile (hysterectomy, bilateral tubal ligation, or\n             bilateral oophorectomy), post menopausal (no menses >12 months), or using a\n             high-efficiency method of contraception such as implant, injectable, combination oral\n             contraceptive, intrauterine device (IUD) or sexual abstinence, or has a vasectomized\n             partner.\n\n          -  If female of childbearing potential, subject is not pregnant, breast-feeding or\n             planning a pregnancy during the study, and has a negative pregnancy test on screening\n             visit.\n\n          -  Able to comprehend and sign an informed consent document and comply with the\n             requirements of the study.\n\n        Exclusion Criteria:\u2022No measurable malignant disease by CT scan or tumor markers.\n\n          -  Life expectancy of \u2264 24 weeks as measured by the Eastern Cooperative Oncology Group\n             (ECOG) performance status.\n\n          -  Age of less than 18 years or over 80 years of age.\n\n          -  Documented/confirmed positive testing for hepatitis B, hepatitis C, HIV, or CMV.\n\n          -  Prior or current history of autoimmune disease.\n\n          -  Pregnant or lactating women.\n\n          -  Leukocyte count < 3,000 /\u03bcL prior to leukapheresis.\n\n          -  Platelet count < 100,000/\u03bcL prior to leukapheresis.\n\n          -  Hemoglobin levels below 10.\n\n          -  PTT (prothrombin time) of < 12 seconds or > than 15 seconds.\n\n          -  aPTT (activated partial thromboplastin time) of < 25 seconds or > than 39 seconds.\n\n          -  Failure or refusal to sign informed consent for the study.\n\n          -  Culture fails to meet specifications for study.\n\n          -  Subject has any other medical condition that, in the opinion of the investigator,\n             might significantly affect the ability to safely participate in the study or affect\n             the conduct of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801852", 
            "org_study_id": "CHN-PLAGH-BT-003"
        }, 
        "intervention": {
            "arm_group_label": "NKT cells", 
            "intervention_name": "NKT cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 2, 2013", 
        "location": {
            "contact": {
                "email": "timothyfkc@yahoo.com.cn", 
                "last_name": "Feng Kaichao, Doctor", 
                "phone": "+86-10-13811421950"
            }, 
            "contact_backup": {
                "email": "immunolzhang@gmail.com", 
                "last_name": "Zhang Minghui, Doctor", 
                "phone": "86-10-13240905431"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100853"
                }, 
                "name": "Biotherapeutic Department of Chinese PLA General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors", 
        "overall_contact": {
            "email": "hanwdrsw@sina.com", 
            "last_name": "Han Weidong, Doctor", 
            "phone": "+86-10-66937463"
        }, 
        "overall_contact_backup": {
            "email": "immunolzhang@gmail.com", 
            "last_name": "Zhang Minghui, Doctor", 
            "phone": "+86-10-13240905431"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee of Chinese PLA General Hospital", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment", 
            "measure": "Occurrence of study related adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Until week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801852"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Han weidong", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Anti-tumor responses to NKT cells infusions", 
            "safety_issue": "No", 
            "time_frame": "at least once within 30 days afther completing four-cycle treatment"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Medical College of Tsinghua University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}